Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses a phase II study of whole brain radiotherapy with concurrent lapatinib in patients with brain metasteses from HER2-positive breast cancer.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More